<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">8761384</article-id><article-id pub-id-type="pmc">2074658</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Phase I trial of elactocin.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Newlands</surname><given-names>E. S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Rustin</surname><given-names>G. J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Brampton</surname><given-names>M. H.</given-names></name></contrib></contrib-group><aff>Department of Medical Oncology, Charing Cross Hospital, London, UK.</aff><pub-date pub-type="ppub"><month>8</month><year>1996</year></pub-date><volume>74</volume><issue>4</issue><fpage>648</fpage><lpage>649</lpage><abstract><p>Elactocin is a novel anti-tumour antibiotic which has potent activity in vitro against a range of tumours. This phase I trial of elactocin identified the dose-limiting toxicity as profound anorexia and malaise. The schedules used included 1 h infusion 3 weekly, 24 h infusion 3 weekly, 1 h infusion daily x 5 (3 weekly), 1 h infusion weekly and finally continuous 5 day intravenous infusion. On all these schedules dose-limiting toxicity was the same and as no partial or complete responses were identified, we do not recommend that further trials of elactocin are performed.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00020-0158.tif" xlink:title="scanned-page" xlink:role="648" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00020-0159.tif" xlink:title="scanned-page" xlink:role="649" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

